Cantor Fitzgerald maintains $118 target on Ultragenyx stock
Cantor Fitzgerald reaffirmed its Overweight rating and $118.00 price target for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company specializing in rare diseases. Currently ...
Cantor Fitzgerald cuts Informatica price target to $18 from $29
Cantor Fitzgerald adjusted its outlook on Informatica (NYSE:INFA) shares by lowering the price target to $18.00 from the ...
Phathom Pharmaceuticals initiated at Cantor Fitzgerald on ‘significant’ upside
Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals (PHAT) with an Overweight rating and $23 price target The firm cited ...
Seabridge Gold Announces US$100 Million in Financings Includes US$20 million from Strategic Investor
Seabridge Gold Inc. (TSX: SEA) (NYSE: SA) ("Seabridge" or the "Company") announced today it has entered into an agreement with RBC Capital Markets and Cantor Fitzgerald Canada Corporation (together ...
Cantor Fitzgerald Remains a Buy on Kornit Digital (KRNT)
In a report released yesterday, Troy Jensen from Cantor Fitzgerald reiterated a Buy rating on Kornit Digital (KRNT – Research Report), with a ...
CVS Health upgraded at Cantor Fitzgerald after Q4 beat
CVS Health (CVS) stock was upgraded by Cantor Fitzgerald to Overweight after the company posted strong Q4 results earlier in ...